List view / Grid view
Mass spectrometry revealed biomarkers that could be used as drug targets for developing novel therapeutics or to predict whether a patient with COVID-19 will become severely ill.
A team used both structural and spectroscopic techniques to study the dynamics of cell surface G-protein coupled receptors (GPCRs).
Collaborative research has revealed two hallmarks of COVID-19 infection associated with more severe symptoms that can be identified by a blood test.
Bioassays and thin-layer chromatography has been used by scientists to analyse molecules in plant extracts as a fast and cost-effective method for identifying new drug compounds.
A novel software made by scientists can be used for the analysis of specific lipid groups and lipid signal molecules which can enable their characterisation with mass spectrometry.
The UK National Institute of Health Research (NIHR) and UK Research and Innovation (UKRI) wish to fund research exploring if people from black, Asian and middle eastern backgrounds are disproportionately at risk from COVID-19.
Researchers discovered the monoclonal antibodies of a convalescent Marburg infection patient bound to the glycoprotein and combatted infection in two novel ways.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
Austrian researchers reveal the first 21 SARS-CoV-2 viral genomes as part of their project to aid in international understanding of how the virus causing COVID-19 mutates.
Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
Organoids at different stages of non-alcoholic steatohepatitis (NASH) progression have been created to help in drug design and identification of diagnostic biomarkers.
Cryogenic electron microscopy revealed that the vitamin B12 transporter on Mycobacterium tuberculosis acts like a non-selective sluice, transporting both the vitamin and antibiotics.
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
